Back to top

Agomab initiated with a Buy at B. Riley

B. Riley initiated coverage of Agomab (AGMB) with a Buy rating and $34 price target The firm sees lead drug ontunisertib as a first mover in fibros...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: